Introduction {#sec1}
============

Oral cavity and oropharyngeal cancers, known as oral carcinomas, are actually heterogeneous diseases with various behaviors. Ninety percent of these diseases are squamous cell carcinomas (SCC) \[[@cit0001]\]. Oral SCC are the 6^th^ most commonly observed malignancy in the world \[[@cit0002]\]. Oral cavity carcinomas arise from the tongue, palate, cheek, retromolar triangle and gingiva \[[@cit0003]\]. Such cancer types are more prevalent among men, yet rising tobacco and alcohol consumption has caused an increasing rate of prognosis among women \[[@cit0003]\]. These tumors are known as rapidly progressive, and distant metastases have been reported in 53% of them \[[@cit0004]\]. Even though early diagnosis and treatment methods have advanced, the 5-year survival rate is 50--55% \[[@cit0005], [@cit0006]\].

Radiotherapy along with surgical treatments is equally successful in early cases of oral cavity carcinomas. Tumors that are at advanced stages require surgical and postoperative radiotherapy. Chemotherapy is also used in these cases \[[@cit0003]\].

Survivin is a member of the inhibitor of apoptosis (IAP) family. Survivin is not found in normal human tissue, but it is expressed in many cancer types. These properties make survivin a prime molecular target for cancer treatment \[[@cit0007]--[@cit0011]\]. There are numerous reports about survivin expression and its correlation with poor prognosis and drug resistance \[[@cit0012]\]. Recent studies have shown that survivin expression has a direct correlation with survival in SCC \[[@cit0013], [@cit0014]\].

Apart from playing a role in progression of cervical cancer in women, human papilloma virus (HPV) has a correlation with carcinogenesis of oral carcinomas \[[@cit0015]\]. Oral HPV infection is related to sexual behavior \[[@cit0016]\]. In oral carcinomas, HPV 16 prevalence was determined as 22% and HPV 18 as 14% \[[@cit0017]\]. HPV plays a significant role (up to 45%) in the etiology of SCC in oropharyngeal, lingual and palatine tonsil carcinomas \[[@cit0018], [@cit0019]\]. Tongue carcinomas have a HPV prevalence of 25% \[[@cit0020]\]. According to some studies, HPV status of tumors has a relation with response to treatment and survival rates, HPV positivity having better results in oropharyngeal carcinomas \[[@cit0021]\].

Both primary and metastatic tumors need nutrients and oxygen. Angiogenesis (neovascularization) is necessary in order to obtain oxygen and nutrition \[[@cit0022]\]. Until tumors reach 2--3 mm in size, tumors can obtain their necessities by diffusion. Afterwards endothelial cells migrate to the stroma by means of angiogenesis stimulation \[[@cit0023]\]. Angiogenic factors were expressed by tumor cells continuously or as responses to external stimulations. Hypoxia, lymphocytes infiltrating tumor, materials secreted by macrophages and mast cells can lead to angiogenesis \[[@cit0024], [@cit0025]\]. Other factors that can lead to an angiogenic response at a micro level include cytokines and growth factors. All of these factors increase the vascular endothelial growth factor (VEGF) expression \[[@cit0026]\].

Tumor angiogenesis leads to increased tumor cell circulation and also increases the possibility of metastasis. In most tumor types, it is observed that a small vein count in the microscopic range leads to an increase in metastasis and decrease in survival rate. Tumor angiogenesis is an important step in tumor growth and metastasis \[[@cit0027]\]. The numerical count of tumor angiogenesis is described as microvessel density (MVD). Antibodies such as CD31, CD34, CD105 and von Willebrand factor (factor VIII), which are specific to vein endothelium, are used for MVD evaluation. Recent studies have shown that MVD is correlated with advanced stage and poor prognosis in tumors of the breast, lung, colon, stomach, skin, prostate and kidney \[[@cit0028], [@cit0029]\].

Angiogenesis, survivin expression and HPV positivity are important factors used for predicting prognosis in oropharyngeal carcinomas. This study aims to identify the prognostic importance of angiogenesis, survivin and HPV positivity in patients treated with curative radiotherapy and chemotherapy.

Material and methods {#sec2}
====================

Patients' selection {#sec2.1}
-------------------

Data and demographic properties of 46 patients who had undergone mucosal biopsy diagnosed as squamous cell carcinoma in the pathology department were included in the study. All of the patients were treated with the radiotherapy-chemotherapy regimen as described below and were evaluated retrospectively. Patients under the age of 18 and those diagnosed with malignancy other than SCC were excluded.

Pathological method {#sec2.2}
-------------------

Tumor staging was assessed according to the 2010 American Joint Committee on Cancer staging criteria \[[@cit0030]\]. Histological grading was performed in a blind manner following the World Health Organization criteria for squamous cell carcinomas of the oral mucosa.

Survivin antibody (polyclonal rabbit, Clone N/A, 1 : 100, Novus Biologicals, Littleton, USA), HPV antibody (cocktail broad spectrum, Clone BPV-1/IH8+CAMVIR-1, 1/80 dilution, Biocare Medical, Concord, USA) and CD34 antibody (polyclonal rabbit, Clone QBEND-10, 1/200, Thermo Scientific, Waltham, Massachusetts, USA) were applied to the 5-micron thick slides obtained from paraffin blocks containing tumoral area. Control tissues were stained colon adenocarcinoma for survivin, infected cervical tissue for HPV and normal kidney tissue for CD34. Sections were deparaffinized by passing through xylene, and rehydrated by a graded series of ethanol. After antigen retrieval by heating in citrate buffer at 60°C in an incubator overnight, the sections were treated with 3% H~2~O~2~ in methanol for 20 min to abolish endogenous peroxidase activity. Then the sections were incubated with CD34 and HPV antibodies for 25 min. Sections were incubated with 2 μg/ml anti-survivin at 48°C overnight. Respectively, anti-polyvalent biotinylated antibody, PBS, anti-polyvalent biotinylated antibody, PBS, AEC substrate and hematoxylin-eosin steps were applied.

Nuclear and cytoplasmic staining of survivin antibody was evaluated. Cases with more than 5% staining in tumors were rated as positive and were graded for staining prevalence in 3 categories: score 0: \< 5%; score 1: 5% to 25%; score 2: 26% to 50%; score 3: 51% to 75%; score 4: \> 75% \[[@cit0013]\].

CD34 antibody was used for assessing microvessel density. Tissues were scanned for the optimum staining point, and then micro veins in the stroma of outlying tumor islands in 10 HPF areas were counted and equated \[[@cit0031]\].

Tumor cells were rated as positive in nuclear staining for HPV antibodies \[[@cit0032]\].

Radiotherapy {#sec2.3}
------------

Patients with locally advanced disease were treated using parallel opposed lateral fields until 2004. After 2004, patients were treated using 3D conformal radiotherapy techniques. 70 Gy of radiotherapy was given to the primary tumor and clinically involved nodes, while 50--60 Gy of radiotherapy was given for subclinical disease.

Chemotherapy {#sec2.4}
------------

All patients were simultaneously given 100 mg/m^2^ of cisplatin for 21-day intervals.

Statistical analysis {#sec2.5}
--------------------

Demographic-clinical characteristic of patients are shown as mean ± standard deviation or number (percentage). Survival times by clinical stage and differentiation were analyzed using Kaplan-Meier survival analysis, then the log-rank test was used for group comparisons. Relationships of survivin and CD34 with clinical stage and differentiation were analyzed using Spearman correlation analysis. Comparisons of survivin and CD-34 level by clinical stage were analyzed by the Mann-Whitney *U* test and Student's *t* test, respectively. Comparisons of survivin and CD-34 level by differentiation were analyzed by the Kruskal-Wallis test and one-way ANOVA test, respectively. Independent effects of demographic-clinical characteristics (age, gender, survivin, CD34, clinical stage and differentiation) on survival were analyzed by a univariate Cox regression model, then we analyzed all likely prognostic factors by multivariate backwards stepwise Cox regression analysis. A *p*-value \< 0.05 was considered statistically significant. Statistical analysis was performed using SPSS 20.0 (IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.).

Results {#sec3}
=======

The average age was 59.48 ±11.43 (min: 31, max: 91). Ten (21.74%) patients were female and 36 (88.26%) were male. Average survival time was 30.94 ±25.24 months.

Clinically, 12 patients (26%) had stage I--II and 34 (74%) patients had stage III--IV disease. We observed a statistically significant correlation between tumor clinical stage and survival (*p* \< 0.006) ([Table I](#t0001){ref-type="table"}).

###### 

Clinical characteristic and average survival time of patients

  Parameter         *N* (%)      Survival \[months\]Mean ± SD   *P*-value      
  ----------------- ------------ ------------------------------ -------------- -------
  Clinical stage    I--II        12 (26.09)                     85.97 ±17.33   0.027
  III--IV           34 (73.91)   32.41 ±6.19                                   
  Differentiation   Good         13 (28.26)                     40.99 ±7.45    0.423
  Moderate          7 (15.22)    23.29 ±5.37                                   
  Poor              26 (56.52)   66.69 ±17.08                                  

Twenty-six (56.5%) patients had poorly differentiated tumors. Seven (15.2%) patients had moderately differentiated tumors and 13 (28.3%) patients had well-differentiated tumors ([Figure 1](#f0001){ref-type="fig"}). We did not observe a statistically significant correlation between differentiation and survival rate (*p* = 0.423) ([Table I](#t0001){ref-type="table"}).

![Microscopic features of oropharyngeal squamous cell carcinoma. **A** -- Well-differentiated type (arrow: keratin pearl), **B** -- Poorly differentiated type, H + E 50×](AMS-13-26437-g001){#f0001}

Survivin scores were 0, 1, 2, 3, 4 respectively in 1 (2.2%), 6 (13.0%), 6 (13.0%), 14 (30.4%), and 19 (41.3%) patients. We detected a significant correlation between survivin positivity and survival rate (*p* \< 0.05) ([Figure 2](#f0002){ref-type="fig"}).

![Immunoperoxidase staining examples. **A** -- Diffuse strongly survivin antibody positivity, 50×, **B** -- Focally moderate survivin positivity, 100×, **C** -- Microvessel density evaluation with CD34 antibody (arrow: a stained vessel) 50×, **D** -- HPV positivity in tumoral cells (arrow: a nuclear positivity), 100×](AMS-13-26437-g002){#f0002}

A positive reaction with HPV antibody was seen in 3 of the patients. We observed no relationship between HPV status and survival rate (*p* \> 0.05).

Microvessel density mean value was 41.26 ±16.13 (min: 12, max: 75). We found a significant correlation between MVD count and survival rate (*p* \< 0.05).

Effects of some demographic and clinical characteristics on survival rate are shown in [Table II](#t0002){ref-type="table"}. Among the variables (survivin, CD34, and clinical stage) that were entered in the backward stepwise Cox regression model, survivin and CD34 were found to be significant prognostic factors for survival. According to this model, survivin positivity increased the mortality risk 3.176-fold (95% CI: 1.539--6.554) and MVD count increased the mortality risk 1.075-fold (95% CI: 1.030--1.123) in patients with oropharyngeal carcinoma.

###### 

Effect of demographic-clinical characteristics on survival

  Parameter          Univariate   Multivariate[\*](#tf2-1){ref-type="table-fn"}                                                 
  ------------------ ------------ ----------------------------------------------- -------------- ------- -------------- ------- ----
  Age                0.978        0.944--1.013                                    0.211          --      --             --      
  Gender, female     1.669        0.662--4.208                                    0.277          --      --             --      
  Survivin           4.922        2.578--9.399                                    \< 0.001       3.176   1.539--6.554   0.002   
  CD34               1.119        1.074--1.166                                    \< 0.001       1.075   1.030--1.123   0.001   
  Stage, III--IV     3.804        1.364--10.606                                   0.011          --      --             --      
  Differentiation:                                                                0.280          --      --             --      
                      Poor        1                                               Reference      0.440   --             --      --
                      Moderate    1.408                                           0.463--4.281   0.547   --             --      --
                      Good        0.635                                           0.255--1.582   0.330   --             --      --

Backward stepwise Cox regression analysis.

Survivin scores and CD-34 levels were higher in patients with clinical stages III--IV (respectively, *p* \< 0.001; *p* = 0.002). In addition, survivin scores and CD-34 levels were significantly higher in patients with moderate differentiation than good differentiation (respectively *p* = 0.045; 0.041) ([Table III](#t0003){ref-type="table"}). Survivin scores and CD-34 levels were significantly correlated with clinical stage (*p* \< 0.001, [Table IV](#t0004){ref-type="table"}).

###### 

Comparisons of survival time, survivin and CD-34 level by clinical characteristics

  Parameter     Clinical stage   *P*-value    Differentiation   *P*-value                              
  ------------- ---------------- ------------ ----------------- ------------ ------------ ------------ -------
  Survivin      1.5 (0--3)       4 (1--4)     \< 0.001          2 (0--4)     4 (2--4)     3 (1--4)     0.045
  CD-34 level   29.4 ±10.9       45.4 ±15.6   0.002             36.0 ±16.1   54.5 ±14.9   40.2 ±15.0   0.041

Mean ± standard deviation; median (minimum -- maximum).

###### 

Correlations between survivin and CD-34 level with clinical characteristics

  Variable      Clinical stage                                  Differentiation
  ------------- ----------------------------------------------- -----------------
  Survivin      *r* = 0.768[^†^](#tf4-1){ref-type="table-fn"}   *r* = --0.211NS
  CD-34 level   *r* = 0.524[^†^](#tf4-1){ref-type="table-fn"}   *r* = --0.036NS

*p* \< 0.001, NS -- non-significant.

Discussion {#sec4}
==========

Recent studies about some carcinoma types are usually geared towards prognosis, prediction of survival, treatment resistance and also target-based treatments \[[@cit0033], [@cit0034]\]. Some studies about oropharyngeal carcinoma are focused on this issue. Recently, a significant correlation was detected between survivin positivity, which is an inhibitor of apoptosis, and carcinogenesis \[[@cit0007]\]. In our study, we observed a direct correlation between survivin levels in oropharyngeal tumors and survival rate, which may help in planning of new medication research about inhibition of the survivin pathway. In our study, as well as parameters such as tumor differentiation and stage, which are known have an effect on prognosis, we studied the effects of survivin, HPV positivity and MVD on survival and demonstrated that all factors that are listed apart from HPV positivity are associated with prognosis.

Survivin is a protein that inhibits apoptosis (a member of inhibitor of apoptosis proteins -- the IAP family). It is thought that survivin protein promotes tumor growth and progression by inhibiting apoptosis and increasing cell proliferation \[[@cit0035]\]. The role of abnormal expression of survivin protein in increased cell proliferation due to molecular carcinogenesis and apoptosis is well documented. Likewise, there are various published studies indicating that survivin is a negative prognostic factor regarding survival. Recent studies have noted that bladder, colon, rectum, lung, stomach and breast cancers all have abnormal expression of the survivin gene \[[@cit0036], [@cit0037]\]. Consistent with all these findings, we observed a significant relationship between survivin staining levels and survival rates. However, Zhang *et al.* \[[@cit0038]\] observed no relation between survivin staining level and survival rates, in contrast with our study. In this study, the univariate analysis demonstrated a 4.9-fold and the multivariate analysis demonstrated a 3.2-fold positive effect of the survivin staining score on survival rate. These results show the direct relation between the survival rate and survivin staining score in the patients.

Angiogenesis, which means formation of new blood vessels, is critical for embryonic progress, normal growth and repair of damaged tissue. At the same time, it can be pathological. Especially, substances secreted by cancerous cells are stimulate to the angiogenesis. For this reason, cancer patients are prescribed anti-angiogenic chemotherapy agents as part of their treatment. Microvessel density is typically assessed feature in studies for angiogenic research and CD34 antibody is a credible marker for MVD evaluation. Recent studies have noted a direct correlation between MVD and poor course of disease in breast, lung, colon, stomach, malign melanoma, prostate and bladder cancer along with advanced pathological stage \[[@cit0039]--[@cit0041]\]. Kyzas *et al.* \[[@cit0042]\] studied microvessel density in 69 patients diagnosed with head and neck cancers. The patient population included oral cavity, larynx and lower lip cancer patients. De Oliveira *et al.* \[[@cit0043]\] observed that patients with locoregional metastases had a higher than average MVD. Another outcome of this study is that the microvascular density has an effect on the survival rate. A slight increase in the microvascular density may reveal a negative effect on survival rate.

Yu *et al.* \[[@cit0044]\] evaluated 1279 head and neck cancer patients' results in a meta-analysis containing data from 18 studies. In their study, mortality rate was determined as 1.23 times more in tumors with high microvessel density, but the difference was not statistically significant. But in our study, we observed a significant correlation between MVD and survival times.

Numerous studies have documented the effect of human papilloma virus on etiology of oropharyngeal carcinomas. Especially, there are many publications about HPV-16's correlation with base of tongue and oropharyngeal cancers \[[@cit0045], [@cit0046]\]. HPV stimulates the p16 INK4a pathway, and many studies have observed a better survival rate among patients who are HPV positive. Kanyilmaz *et al.* \[[@cit0047]\] reported that tumor positivity for p16 INK4a was correlated with improved disease-free survival and overall survival. However, we did not observe a correlation between HPV positivity and survival. This might be a result of the small number of HPV-positive cases in our study.

In our study, survivin levels and MVD were determined as effective prognostic factors and related to survival in oropharyngeal cancers. New treatment methods might be discovered in light of the relationship of survivin levels which is an inhibitor of apoptosis and is a significant factor in carcinogenesis with survival rates. An agent leading to blockage of survivin expression might be used as an alternative objective-oriented medication for oropharyngeal carcinomas.

The significant correlation between MVD in oropharyngeal carcinomas and survival leads us to believe that objective-oriented treatment agents targeting angiogenesis stages might be effective against this tumor group.

In conclusion, survivin levels and angiogenesis were determined as effective prognostic factors and were related to survival in oral cavity and oropharyngeal cancers. Treatments targeting survivin expression and angiogenesis might be employed against these tumor groups.
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